Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy.


Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 20 11 2021
revised: 08 02 2022
accepted: 16 03 2022
pubmed: 23 3 2022
medline: 6 5 2022
entrez: 22 3 2022
Statut: ppublish

Résumé

To evaluate the risk algorithm by Aspelund et al. for predicting sight-threatening diabetic retinopathy (STDR) in Type 2 diabetes (T2D), and to develop a new STDR prediction model. The Aspelund et al. algorithm was used to calculate STDR risk from baseline variables in 1012 participants in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) ophthalmological substudy, compared to on-trial STDR status, and receiver operating characteristic analysis performed. Using multivariable logistic regression, traditional risk factors and fenofibrate allocation as STDR predictors were evaluated, with bootstrap-based optimism-adjusted estimates of predictive performance calculated. STDR developed in 28 participants. The Aspelund et al. algorithm predicted STDR at 2- and 5-years with area under the curve (AUC) 0.86 (95% CI 0.77-0.94) and 0.86 (0.81-0.92), respectively. In the second model STDR risk factors were any DR at baseline (OR 24.0 [95% CI 5.53-104]), HbA1c (OR 1.95 [1.43-2.64]) and male sex (OR 4.34 [1.32-14.3]), while fenofibrate (OR 0.13 [0.05-0.38]) was protective. This model had excellent discriminatory ability (AUC = 0.89). The algorithm by Aspelund et al. predicts STDR well in the FIELD ophthalmology substudy. Logistic regression analysis found DR at baseline, male sex, and HbA1c were predictive of STDR and, fenofibrate was protective.

Identifiants

pubmed: 35314259
pii: S0168-8227(22)00647-7
doi: 10.1016/j.diabres.2022.109835
pii:
doi:

Substances chimiques

Glycated Hemoglobin A 0
Fenofibrate U202363UOS

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109835

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Benjamin N Rao (BN)

NHMRC Clinical Trials Centre, The University of Sydney, Australia; Faculty of Medicine, Nursing and Health Sciences, Monash University, Australia.

Nicola Quinn (N)

NHMRC Clinical Trials Centre, The University of Sydney, Australia; Centre for Public Health, Queens University, Belfast, Northern Ireland, United Kingdom.

Andrzej S Januszewski (AS)

NHMRC Clinical Trials Centre, The University of Sydney, Australia.

Tunde Peto (T)

Centre for Public Health, Queens University, Belfast, Northern Ireland, United Kingdom.

Laima Brazionis (L)

Department of Medicine, St. Vincent's Hospital Campus, The University of Melbourne, Australia.

Nanda Aryal (N)

NHMRC Clinical Trials Centre, The University of Sydney, Australia.

Rachel L O'Connell (RL)

NHMRC Clinical Trials Centre, The University of Sydney, Australia.

Liping Li (L)

NHMRC Clinical Trials Centre, The University of Sydney, Australia.

Paula Summanen (P)

Department of Ophthalmology, Helsinki University Hospital, University of Helsinki, Finland.

Russell Scott (R)

Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand.

Justin O'Day (J)

Department of Ophthalmology, Royal Victorian Eye and Ear Hospital, The University of Melbourne, Australia.

Anthony C Keech (AC)

NHMRC Clinical Trials Centre, The University of Sydney, Australia.

Alicia J Jenkins (AJ)

NHMRC Clinical Trials Centre, The University of Sydney, Australia; Centre for Public Health, Queens University, Belfast, Northern Ireland, United Kingdom; Department of Medicine, St. Vincent's Hospital Campus, The University of Melbourne, Australia. Electronic address: Alicia.Jenkins@sydney.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH